Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA or HRR+ Mutated Ovarian Cancer Patients”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Not Yet RecruitingNCT07088588
What this trial is testing

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+3 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 105
Early research (Phase 1)Looking for participantsNCT06666270
What this trial is testing

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 30
Post-approval studies (Phase 4)Study completedNCT02476968
What this trial is testing

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Who this might be right for
BRCA or HRR+ Mutated Ovarian Cancer Patients
AstraZeneca 181
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca